The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
PAT after MI is Rs. 41 crore which is 162% increase
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
The brand Magtein by Threotech has a sales value of approximately US $438 million
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Acquisition expands high-value medical platform
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
Subscribe To Our Newsletter & Stay Updated
